

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

AMNEAL PHARMACEUTICALS LLC  
*Petitioner,*

v.

CUBIST PHARMACEUTICALS LLC  
*Patent Owner*

---

Case IPR2020-00193  
U.S. Patent No. 9,138,456

---

**PATENT OWNER'S PRELIMINARY RESPONSE  
PURSUANT TO 37 C.F.R. § 42.107**

**TABLE OF CONTENTS**

	<b><u>Page</u></b>
I. INTRODUCTION .....	1
II. THE STATE OF THE ART & THE '456 PATENT .....	5
A. The '456 Patent & The Challenged Claims Unexpectedly Provide Long term Stability At Room Temperature and Faster Reconstitution Time .....	5
B. The Original Cubicin® Product And The Alleged Need For An Improved Product Capable of Room Temperature Storage.....	7
C. Methods For Improving Peptide And Protein Stability In Lyophilized Formulations Were Highly Unpredictable and Compound-Dependent .....	9
III. SCOPE AND CONTENT OF THE ART .....	11
A. The Cubicin® Label (Ex. 1004).....	11
B. The Caspofungin (Cancidas®) Label (Ex. 1010).....	12
C. Neururkar (Ex. 1005) .....	13
D. Mittal (Ex. 1007) .....	14
E. Sawai (Ex. 1006) .....	18
F. Inman (Ex. 1008).....	20
G. Level of Ordinary Skill in the Art .....	21
H. Claim Construction.....	21
IV. THE PETITION FAILS TO ESTABLISH A REASONABLE LIKELIHOOD THAT CLAIMS 1, 2, AND 7-11 WOULD HAVE BEEN OBVIOUS IN VIEW OF ITS TWO ASSERTED GROUNDS .....	21
A. The Petition Fails To Provide Even A <i>Prima Facie</i> Motivation or Reason To Combine for Grounds 1 or 2.....	23
1. Petitioner Has Not Shown That A POSA Would Be Motivated To Consider Caspofungin Compositions When Formulating Daptomycin .....	25
2. Neururkar Does Not Teach or Disclose Any Lyophilized Formulations That Are Stable At Room Temperature .....	28

3.	Mittal Teaches That The Use Of Sucrose Will Not Improve Stability Above Refrigerated Temperatures.....	31
4.	Sawai Does Not Disclose Any Lyophilized Formulations Using Sucrose That Are Stable At Room Temperature.....	36
B.	Grounds 1 And 2 Also Fail For Failure To Establish Even A <i>Prima Facie</i> Basis For a Reasonable Expectation of Success .....	38
1.	Petitioner’s Two-Sentence Argument Does Not Establish A <i>Prima Facie</i> Basis For An Expectation of Success .....	39
2.	Petitioner’s Expectation Of Success Argument Conflicts With The Teachings Of Neururkar And Mittal .....	42
3.	Petitioner Also Fails To Deal With The Teachings That Methods Of Stabilization For One Active Ingredient Cannot Be Applied To Another With Any Reasonable Expectation Of Success.....	42
C.	The Additional References That Petitioner Relies Do Not Support Its Arguments .....	44
1.	The Board Should Not Consider Additional References Cited By Petitioner.....	45
2.	The Additional References Cited By Petitioner Do Not Provide A Motivation Or Reasonable Expectation Of Success .....	46
D.	Dr. Suryanarayanan’s Conclusory Declaration Does Not Establish Motivation and Reasonable Expectation of Success .....	51
E.	Secondary Considerations Support Non-Obviousness .....	53
1.	Unexpected Enhanced Stability .....	54
2.	Unexpected Improved Reconstitution Time .....	58
V.	CONCLUSION.....	61

**TABLE OF AUTHORITIES**

**Page**

**CASES**

*Allergan, Inc. v. Sandoz Inc.*,  
796 F.3d 1293 (Fed. Cir. 2015) .....60

*In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig.*,  
676 F.3d 1063 (Fed. Cir. 2012) .....53

*Forest Labs., LLC v. Sigmapharm Labs., LLC*,  
918 F.3d 928 (Fed. Cir. 2019) .....22

*Initiative for Medicines, Access & Knowledge (I-Mak), Inc. v. Gilead Pharmasset LLC*,  
IPR2018-00119, Paper (PTAB May 4, 2018) .....52

*Initiative for Meds., Access & Knowledge (IMak), Inc. v. Gilead Pharmasset LLC*,  
IPR2018-00103, Paper (PTAB June 13, 2018) .....52

*K/S Himpp v. Hear-Wear Techs., LLC*,  
751 F.3d 1362 (Fed. Cir. 2014) .....52

*Leo Pharm. Prods., Ltd. v. Rea*,  
726 F.3d 1346 (Fed. Cir. 2013) .....53

*Mylan Pharms. Inc. v. Research Corp. Techs., Inc.*,  
914 F.3d 1366 (Fed. Cir. 2019) .....5

*Ortho-McNeil Pharm., Inc. v. Mylan Labs., Inc.*,  
520 F.3d 1358 (Fed. Cir. 2008) .....53

*Otsuka Pharm. Co. v. Sandoz, Inc.*,  
678 F.3d 1280 (Fed. Cir. 2012) .....26

*Procter & Gamble Co. v. Teva Pharms. USA, Inc.*,  
566 F.3d 989 (Fed. Cir. 2009) .....53

*QuantifiCare, Inc. v. Procter & Gamble Co.*,  
IPR2017-02113, Paper (PTAB Mar. 16, 2018).....34

*Smiths Indus. Med. Sys., Inc. v. Vital Signs, Inc.*,  
183 F.3d 1347 (Fed. Cir. 1999) .....22

*In re Soni*,  
54 F.3d 746 (Fed. Cir. 1995) .....53

*Unified Patents Inc. v. Custom Media Techs. LLC*,  
IPR2015-00516, Paper, (PTAB June 25, 2015) .....53

*Winner Int’l Royalty Corp. v. Wang*,  
202 F.3d 1340 (Fed. Cir. 2000) .....54

*Zetec, Inc. v. Westinghouse Elec. Co.*,  
Case IPR2014-00384 (PTAB July 23, 2014) .....35

**STATUTORY AUTHORITIES**

35 U.S.C. § 311(b) .....52

35 U.S.C. § 312(a)(3).....45

35 U.S.C. § 314(a) .....46

**RULES AND REGULATIONS**

37 C.F.R. § 42.24(a).....62

37 C.F.R. § 42.24(a)(i).....62

37 C.F.R. § 42.24 (b)(1).....62

37 C.F.R. § 42.65(a).....52

37 C.F.R. § 42.104(b)(4)..... 45, 46

37 C.F.R. § 42.107 .....1

37 C.F.R. § 42.108(b) .....46

**ADDITIONAL AUTHORITIES**

November 2019, Patent Trial and Appeal Board Consolidated Trial Practice  
Guide (Ex. 2006) .....49

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.